Genomics and Bioinformatics Group web site development and maintenance.

我们继续我们已经成功地维护和扩展了我们的Discover基于Web的工具，重点是CellMiner。我们的CellMiner“NCI-60分析工具”部分为药物基因组学整合、研究和发现提供了重要的资源。它目前是五种工具的宿主，所有这些工具都旨在减少科学家整合分子和药理学数据所需的时间。在过去的一年里，已经进行了四个实质性的升级，i)“基因DNA拷贝数”签名，ii)“遗传变异总和”签名，iii)“DNA的图形输出：外显子组测序”，以及iv)“遗传变异与药物可视化”。介绍了NCI-60的两个新数据库，用于阵列比较基因组杂交的DNA拷贝数和所有基因的外显子组测序。CellMiner的数据和工具正在为癌症患者的合理药物发现、应用和个体化治疗方面的进展创造重大机会。由于多种类型的分子改变可以影响治疗结果，基因组和生物信息学小组(GBG)以这样一种方式管理和整合分子和药理学数据，以加强理解，并促进在药理学背景下产生可检验的假说。因此，GBG除了提供有助于理解、挖掘和利用这些数据的软件资源外，还提供对高吞吐量数据的访问。利用我们在分子生物学、分子药理学、生物统计学、生物信息学和计算机科学方面的专业知识，我们继续生成公共数据库和软件来查询和挖掘这些数据。DTP不断扩大药物数据库，包括进入临床试验的新药。NCI-60是迄今为止最全面的哺乳动物细胞图谱。目前，我们的Discover和CellMiner网站每月有来自73个国家的数千名个人用户。它在过去是这样做的，目前仍在继续带来翻译发现。

We continueWe have successfully maintained and expanded our Discover web-based tools, with emphasis on CellMiner. Our CellMiner "NCI-60 Analysis Tools" section is providing a significant resource for pharmacogenomic integration, research, and discovery. It is currently the host for five tools, all of which are designed to reduce the time required by the scientist to integrate molecular and pharmacological data. Within the last year, four substaintial upgrades have been made, i) "Gene DNA copy number" signatures, ii) "Genetic variant summation" signatures, iii)"Graphical output for DNA: Exome sequencing", and iv) "Genetic variant versus drug visualization". Two new databases for the NCI-60 have been introduced, for DNA copy number from array comparative genomic hybridization hybridization, and exome sequencing of all genes. The CellMiner data and tools are creating major opportunities for progress in rational drug discovery, application, and individualization of therapy for cancer patients. As molecular alterations of many types can contribute to the outcome of therapy, the Genomic and Bioinformatics Group (GBG) manages and integrate molecular and pharmacological data in such a way that enhances understanding, and facilitates the generation of testable hypotheses in the context of pharmacology. The GBG thus provides access to high throughput data, in addition to providing software resources that facilitate the understanding, mining and exploitation of these data. Using our expertise in molecular biology, molecular pharmacology, biostatistics, bioinformatics, and computer science, we continue to generated public databases, and software to query and mine those data. The drug database is continuously expanded by the DTP, including new drugs entering clinical trials. The NCI-60 is by far the most comprehensively profiled panel of mammalian cells anywhere. Currently our Discover and CellMiner sites have thousands of individual users from 73 countries per month. It has in the past and currently continues to lead to translational discoveries.